Theseus Pharmaceuticals Inc

$9.94 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Theseus Pharmaceuticals Inc

Theseus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on treating cancer patients through the discovery, development and commercialization of targeted therapies. Its development programs are designed to address drug resistance mutations in oncogenes, which are mutated genes that cause cancer. The Company is focused on developing tyrosine kinase inhibitors (TKI), which is rooted in the critical role that tyrosine kinases play in the development of cancer. It is focused to development of pan-variant kinase inhibitors that target all cancer causing and drug resistance mutations in clinically protein kinases. The Company's product candidate, THE-630, is a pan-variant inhibitor of all classes of activating and resistance mutations of the KIT kinase, or a pan-KIT inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), a type of cancer characterized by oncogenic activation of KIT.

Stock Analysis

last close $10.31
1-mo return 12.9%
3-mo return -35.6%
avg daily vol. 182.49T
52-week high 24.54
52-week low 8.65
market cap. $458M
forward pe -
annual div. -
roe -
ltg forecast -
dividend yield -
annual rev. $--
inst own. 64.6%

Subscribe now for daily local and international financial news